Current Issue: November 2026
Feature Article
PARP Inhibitors in Metastatic Prostate Cancer: Current Evidence and Future Directions
Abstract: Inhibitors of poly(ADP-ribose) polymerase (PARPis) are an established treatment for homologous recombination repair gene-altered metastatic prostate cancer. The efficacy of PARPis—both as single agents and […]
Feature Article
From ADAURA to LAURA: The Evolving Role of EGFR-Targeted Therapy in NSCLC
Abstract: Epidermal growth factor receptor gene (EGFR) mutations, most commonly involving exon 19 deletion or leucine-858-to-arginine substitution (L858R), define a biologically distinct subset of non–small cell […]
Advances in LLM
Lessons and Limitations of the PARADIGM Trial in Acute Myeloid Leukemia
H&O The combination of a hypomethylating agent (HMA) and venetoclax (Venclexta, AbbVie) is approved as frontline therapy for older, unfit patients with acute myeloid leukemia (AML). […]
Drug Development
Approval Versus Coverage: The Differences Between FDA and CMS Standards
H&O What is the standard that the US Food and Drug Administration (FDA) uses to evaluate a new drug or device? DH The FDA uses safety […]
Supplements:
Therapeutic Approaches in aRCC: Focus on Patient Selection for IO–IO vs IO–TKI
Therapeutic Approaches in aRCC: Focus on Patient Selection for IO–IO vs IO–TKI In the Clinic . . . Patient 1: Metastatic Recurrence 2 Years After Completing […]
How I Treat MDS/AML: Individualizing Therapy Based on Disease Biology, Patient Fitness, Molecular Features, and Treatment Goals
How I Treat MDS/AML: Individualizing Therapy Based on Disease Biology, Patient Fitness, Molecular Features, and Treatment Goals In the Clinic . . . Consider the following […]